NXgenPort Company Profile

Background

Overview

NXgenPort is a biomedical technology company specializing in remote patient monitoring for cancer care. The company has developed an innovative implantable chemo-port catheter integrated with microchip and sensor technology, enabling real-time monitoring of physiological functions in cancer patients. This advancement aims to enhance early detection of complications, improve patient outcomes, and reduce hospitalizations.

Mission and Vision

NXgenPort's mission is to revolutionize cancer care by providing continuous, remote monitoring of patients undergoing chemotherapy. The vision is to empower healthcare providers with actionable data, facilitating proactive management of patient health and optimizing treatment efficacy.

Primary Area of Focus

The company's primary focus is on developing and commercializing implantable devices that combine drug delivery with continuous at-home monitoring of critical health metrics, such as white blood cell counts, vital signs, and heart function. This approach aims to detect early signs of infection and other complications, thereby improving patient care and reducing healthcare costs.

Industry Significance

In the rapidly evolving field of digital health and personalized medicine, NXgenPort stands out by integrating sensor technology into implantable devices. This innovation addresses a significant gap in cancer care by enabling remote monitoring, which is crucial for early intervention and improved patient outcomes.

Key Strategic Focus

Core Objectives

• Remote Monitoring: Implement continuous, real-time monitoring of cancer patients to detect early signs of complications.

• Data Analytics: Utilize collected data to provide actionable insights for healthcare providers, facilitating timely interventions.

• Patient Management: Enhance patient engagement and adherence to treatment plans through accessible monitoring tools.

Specific Areas of Specialization

• Implantable Medical Devices: Design and development of implantable chemo-port catheters equipped with advanced sensor technology.

• Remote Patient Monitoring: Integration of sensor data with digital health platforms to enable remote monitoring and management.

• Data Analytics: Application of machine learning algorithms to analyze physiological data for early detection of health issues.

Key Technologies Utilized

• Microchip and Sensor Technology: Embedded within the implantable device to monitor physiological parameters.

• Machine Learning Algorithms: Analyze collected data to identify trends and potential health risks.

• Digital Health Platforms: Coordinate data between patients and healthcare providers, facilitating remote monitoring.

Primary Markets Targeted

• Healthcare Providers: Hospitals and clinics seeking to enhance patient care through remote monitoring.

• Cancer Patients: Individuals undergoing chemotherapy who can benefit from continuous health monitoring.

• Pharmaceutical Companies: Organizations interested in utilizing remote monitoring data for clinical trials and drug efficacy studies.

Financials and Funding

Funding History

NXgenPort has engaged in multiple funding rounds to support its development and commercialization efforts. The company has secured investments from various sources, including venture capital firms and strategic partnerships. Notably, NXgenPort participated in the MedTech Innovator's 2023 Accelerator Cohort, gaining access to industry leaders, mentorship, and strategic resources.

Total Funds Raised

While specific figures are not publicly disclosed, NXgenPort has successfully attracted funding to advance its product development and expand its intellectual property portfolio.

Recent Funding Rounds

• MedTech Innovator Accelerator Program (2023): Participation in this program provided NXgenPort with non-dilutive funding and strategic support.

Notable Investors

• Groove Capital: Participated in multiple seed funding rounds, contributing to the company's early-stage development.

• MedTech Innovator: Provided non-dilutive funding and strategic support through its accelerator program.

Intended Utilization of Capital

The raised capital is primarily allocated towards product development, including prototype refinement, clinical testing, and regulatory approvals. Additionally, funds support the expansion of the company's intellectual property portfolio and strategic partnerships to enhance market reach.

Pipeline Development

Key Pipeline Candidates

• Implantable Chemo-Port Catheter: An advanced device integrating sensor technology for remote monitoring of cancer patients.

Stages of Development

• Prototype Development: Ongoing refinement of the device design and functionality.

• Pre-Clinical Testing: Scheduled to commence animal testing, with human trials anticipated to begin toward the end of 2025.

Target Conditions

• Cancer Treatment Complications: Focusing on early detection of infections, neutropenia, cardiotoxicity, and other chemotherapy-related issues.

Anticipated Milestones

• Animal Testing: Initiation of pre-clinical studies to validate device functionality.

• Human Clinical Trials: Expected to begin in late 2025, pending regulatory approvals.

Technological Platform and Innovation

Proprietary Technologies

• Implantable Chemo-Port Catheter: A device combining drug delivery with continuous monitoring capabilities.

• Sensor Technology: Embedded sensors for real-time measurement of physiological parameters.

Significant Scientific Methods

• In Vivo Monitoring: Continuous assessment of blood cell counts, heart function, and other vital signs.

• Data Analytics: Utilization of machine learning algorithms to interpret complex physiological data.

AI-Driven Capabilities

• Predictive Analytics: Identifying potential health risks and complications before they manifest clinically.

• Decision Support: Providing healthcare providers with actionable insights to inform treatment decisions.

Leadership Team

Cathy Skinner, MA – Chief Executive Officer

• Professional Background: Entrepreneur with over 12 years of experience in startup environments, including roles at Thrivors.com and TheArtofWell.com.

• Key Contributions: Co-founded NXgenPort, leading the strategic direction and operational execution of the company.

Rosanne Welcher, PhD, MBA, RAC – Chief Operating Officer

• Professional Background: Award-winning R&D and business leader with over 25 years in medical devices and in vitro diagnostics.

• Key Contributions: Co-founded NXgenPort, overseeing product development, regulatory affairs, and quality assurance.

Kelly Christian, MS – Vice President of R&D and Engineering

• Professional Background: Biomedical engineer with 30 years of experience in medical device development, including the first PowerPort™.

• Key Contributions: Leading the R&D efforts at NXgenPort, focusing on device design and engineering.

Rich Nazarian, BS, MS – Advisor

• Professional Background: Former CEO and Founder of Minnetronix Medical, with extensive experience in medical device development and manufacturing.

• Key Contributions: Provides strategic guidance on business growth and product development.

Nancy Lelicoff, MS – Advisor

• Professional Background: Independent Quality and Regulatory Affairs advisor with experience in medical devices and biotech industries.

• Key Contributions: Offers expertise in quality assurance and regulatory compliance to ensure product standards.

Competitor Profile

Market Insights and Dynamics

The market for remote patient monitoring in oncology is expanding, driven by the need for continuous patient engagement and early detection of complications. Advancements in sensor technology and data analytics are facilitating the development of innovative solutions like NXgenPort's implantable devices.

Competitor Analysis

• Current Health: Offers remote patient monitoring solutions with a focus on chronic disease management.

• Biofourmis: Provides digital therapeutics and remote monitoring platforms for various health conditions.

Strategic Collaborations and Partnerships

• Mayo Clinic: Entered into a license agreement to advance development and product testing efforts.

• MedTech Innovator: Selected for the 2023 Accelerator Cohort, providing access to industry leaders and strategic resources.

Operational Insights

NXgenPort differentiates itself through its focus on implantable devices specifically designed for cancer patients, integrating drug delivery with continuous monitoring. This specialized approach addresses unique challenges in oncology care, setting it apart from broader remote monitoring solutions.

Strategic Opportunities and Future Directions

The company plans to expand its product offerings to include monitoring solutions for other